Auto Draft

Sarepta Therapeutics Inc. (NASDAQ:SRPT) is one of the 10 Stocks Investors Are Buying Now.

Sarepta Therapeutics soared by 34.98 percent on Wednesday to finish at $23.77 apiece, as investors took path from Morgan Stanley’s 25-percent price target upgrade for its stock following strong clinical results from two of its rare disease drug candidates.

In a market note, Morgan Stanley raised its price target for Sarepta Therapeutics Inc. (NASDAQ:SRPT) to $25 from $20, while maintaining an “equal weight” rating for the stock.

Praxis Precision Medicines, Inc. (PRAX) Gains Analyst Confidence With Ulixacaltamide

Photo by Suzy Hazelwood on Pexels

The coverage followed the strong results of its SRP-1001 and SRP-1003, in treating patients with facioscapulohumeral muscular dystrophy (FSHD) and myotonic dystrophy type 1, respectively, with results showing a 90 percent reduction of the target protein or mRNA after a single dose, as compared with the 50 to 60 percent range from its competitors.

FSHD and DM1 are rare genetic diseases that are caused by othe verexpression of mutant proteins or toxic mRNA.

“We are pleased that these early clinical results showed high levels of siRNA delivery to muscle, with no saturation of muscle siRNA uptake or dose-limiting safety signals to date. We believe this supports the differentiated potential of this siRNA platform and strengthens our belief that this approach could meaningfully change the treatment landscape for patients with FSHD and DM1,” said Louise Rodino-Klapac, president of the research & development and technical Operations for Sarepta Therapeutics Inc. (NASDAQ:SRPT).

“These preliminary clinical data show consistent dose-dependent increases in plasma and muscle drug exposures across clinical and nonclinical studies and suggest that the αvβ6 integrin-targeting ligand mediates robust siRNA muscle delivery, which we hypothesize will ultimately enable higher dosing and translate into clinical efficacy for patients with FSHD1 and DM1,” she noted.

While we acknowledge the risk and potential of SRPT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than SRPT and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.